Editorial: Why Pfizer won't come back for AstraZeneca
This article was originally published in Scrip
I'm going to stick my neck out. Here I go: Pfizer is not going to come back with another bid for AstraZeneca. Of course, I called it completely wrong over Viehbacher (Lose his job? Don't be silly! Sanofi has never looked better, despite the US diabetes debacle). And admittedly I have waited until quite late in the day on 26 November (the first day that Pfizer could come back with a new bid under UK takeover code rules) to go public with my prophecy.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.